H.R.2300 directs the Secretary of Health and Human Services, via the Commissioner of Food and Drugs, to study the availability of preterm infant formula in the United States and to review existing federal and state laws governing its design, development, testing, manufacture, distribution, sale, labeling, licensing, and safety. The bill also asks whether the Federal Food, Drug, and Cosmetic Act should be amended to require premarket approval for preterm infant formula and, if so, to outline a process for such approval.
In parallel, the act creates a two-year period of temporary federal preemption, preventing states from imposing different or additional requirements on preterm formula, with limited exceptions for willful misconduct, a removal option to federal court, and a requirement to dismiss pending actions that seek to enforce preempted rules. A report detailing the study results and any recommended regulatory changes must be submitted to Congress within two years of enactment.
At a Glance
What It Does
The bill requires a formal study of availability and existing regulation for preterm infant formula, and, if warranted, a pathway for FDA premarket approval. It also imposes a temporary, nationwide preemption of conflicting state requirements during the study period.
Who It Affects
Manufacturers and distributors of preterm infant formula, regulatory agencies at the federal and state levels, hospitals and NICUs, and the broader supply chain.
Why It Matters
If enacted, it would harmonize state rules with federal standards in the near term, potentially altering how formula is developed, tested, labeled, and brought to market while exposing the pathway for FDA oversight expansion.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill begins by directing the Department of Health and Human Services to study preterm infant formula: how readily it is available in the United States and how current federal and state rules affect its design, testing, manufacturing, marketing, labeling, and safety. It also asks whether the FD&C Act should be changed to require FDA premarket approval for preterm formula, and, if so, to propose a concrete process for that approval.
A separate, two-year window would temporarily preempt state laws and regulations related to preterm formula, to ensure nationwide consistency with federal rules. During this period, states could not enforce rules that differ from federal requirements or that add new safeguards beyond those already covered by federal law.
The bill preserves narrow exceptions for civil or criminal actions based on willful misconduct in manufacturing that caused death or serious injury, and it allows removal of such actions from state court to federal court, with a clear standard of proof. If a case was already in court when the bill becomes law, those seeking enforcement of preempted requirements can be dismissed.
The bill also defines critical terms, such as what counts as a “preterm infant formula” and who qualifies as a “manufacturer.” Finally, it requires a congressionally-referenced report within two years detailing findings and any recommended regulatory steps.
The Five Things You Need to Know
The bill directs an FDA-led study of availability and current rules on preterm infant formula.
It contemplates a possible FD&C Act amendment to require premarket approval for preterm formula.
There is a two-year period of temporary federal preemption of state requirements for preterm formula.
Civil/criminal actions for willful misconduct related to formula manufacturing are protected by explicit exceptions and can be removed to federal court.
Pending state actions aimed at enforcing preempted requirements may be dismissed.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Study and potential premarket approval considerations
Section 1(a) requires the Secretary of Health and Human Services, through the FDA Commissioner, to study the availability of preterm infant formula and to assess how current federal and state laws regulate its design, development, testing, manufacture, distribution, labeling, licensing, and safety. It also asks whether the FD&C Act should be amended to require premarket approval for such formula and, if so, to propose a process for that approval. The two-year deadline for final recommendations is explicit in the statute, tying regulatory evolution to a defined timeframe.
Temporary preemption of state requirements
Section 1(b) establishes a two-year window during which no state or political subdivision may enact or enforce requirements related to preterm infant formula that differ from or go beyond federal standards. The preemption covers design, testing, manufacture, packaging, labeling, licensing, safety, and related aspects, aligning state policy with federal law under the FD&C Act, the Poison Prevention Packaging Act, and the Fair Packaging and Labeling Act.
Exceptions to preemption and removal to federal court
Section 1(b)(3) provides an exception for civil or criminal actions based on willful misconduct in manufacturing that caused death or serious injury. It also allows removal of such cases from state court to federal court, with burden of proof set to clear and convincing evidence, ensuring a rigorous standard before a court can find preemption insufficient.
Dismissal of pending actions
Section 1(b)(4) mandates dismissal of civil or criminal actions that were pending at enactment to the extent they seek enforcement of a preempted requirement. This ensures that preempted state standards do not continue to advance through litigation once the federal framework is recognized.
Definitions
Section 1(c) provides key definitions. It clarifies that the term infant formula follows the FD&C Act’s definition; defines “manufacturer” as an entity that changes the characteristics, packages, or labels a preterm formula for distribution (excluding those acting solely to care for a specific infant); defines “preterm infant formula” as formula exempt under 412(h)(1) intended for preterm or low-birth-weight infants; and defines “willful misconduct” with emphasis on intentional wrongdoing, lack of justification, and a risk level that makes harm highly probable.
Implementation and reporting expectations (definitions and scope)
The section further outlines the practical scope for the study and potential regulatory changes, emphasizing how federal premarket pathways, if adopted, would integrate with existing federal and state regulatory structures. It also clarifies the meaning of critical terms to avoid ambiguity in enforcement, labeling, and safety requirements for preterm formula.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- National manufacturers of preterm infant formula with multi-state distribution benefit from uniform federal standards reducing compliance complexity.
- Hospitals and NICUs benefit from a consistent supply chain and clearer expectations for product safety and labeling across states.
- Parents and families of preterm infants stand to gain from potentially safer, more consistently regulated products and improved access.
- FDA and federal policymakers benefit from streamlined oversight and reduced regulatory fragmentation.
- Distributors and retailers benefit from uniform labeling and packaging expectations across markets.
Who Bears the Cost
- Manufacturers may incur costs if premarket approval becomes required, including process development, testing, and compliance investments.
- State and local regulators might face transitional costs as they align with or adjust to federal standards during the preemption period.
- Healthcare providers could experience procurement and supply-chain costs if interim supply dynamics shift due to regulatory changes.
- Payers and insurers could see pricing or reimbursement implications tied to changes in product availability or regulatory compliance.
- Small manufacturers with limited regulatory staff may bear a disproportionate burden if premarket processes are substantial.
Key Issues
The Core Tension
Balancing nationwide uniformity and anticipated safety benefits with the loss of state autonomy and the risk that a federal standard may not capture local needs or rapid market changes.
The bill’s approach aims to reduce state-by-state regulatory fragmentation by leveraging a federal framework. That can improve consistency in product safety, labeling, and access to formula for vulnerable populations.
However, the temporary preemption raises questions about how states might respond to local safety concerns, and whether a two-year window is long enough to implement meaningful regulatory scrutiny or to adjust supply chains if a premarket approval process becomes part of federal policy. The potential cost and time impact of a premarket approval pathway could slow innovation or entry for some manufacturers, even as it creates clearer federal expectations.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.